Wall Street brokerages predict that Anavex Life Sciences Corp (NASDAQ:AVXL) will report ($0.12) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Anavex Life Sciences’ earnings. Anavex Life Sciences posted earnings per share of ($0.09) in the same quarter last year, which suggests a negative year over year growth rate of 33.3%. The firm is scheduled to report its next earnings results on Wednesday, February 6th.
On average, analysts expect that Anavex Life Sciences will report full year earnings of ($0.39) per share for the current fiscal year. For the next year, analysts anticipate that the firm will post earnings of ($0.36) per share. Zacks’ earnings per share averages are a mean average based on a survey of sell-side research analysts that cover Anavex Life Sciences.
Anavex Life Sciences (NASDAQ:AVXL) last posted its earnings results on Wednesday, December 12th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02).
AVXL stock opened at $2.03 on Tuesday. The company has a market cap of $95.04 million, a P/E ratio of -5.21 and a beta of 2.13. Anavex Life Sciences has a 1-year low of $1.25 and a 1-year high of $4.35.
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Laurion Capital Management LP bought a new stake in Anavex Life Sciences in the 2nd quarter valued at $134,000. Jane Street Group LLC bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at $157,000. Paloma Partners Management Co bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at $502,000. Finally, Millennium Management LLC bought a new stake in shares of Anavex Life Sciences during the 2nd quarter valued at $1,749,000. Institutional investors and hedge funds own 17.61% of the company’s stock.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Featured Story: Swap
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.